KR101413616B1 - 트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도 - Google Patents

트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도 Download PDF

Info

Publication number
KR101413616B1
KR101413616B1 KR1020097010871A KR20097010871A KR101413616B1 KR 101413616 B1 KR101413616 B1 KR 101413616B1 KR 1020097010871 A KR1020097010871 A KR 1020097010871A KR 20097010871 A KR20097010871 A KR 20097010871A KR 101413616 B1 KR101413616 B1 KR 101413616B1
Authority
KR
South Korea
Prior art keywords
cholesterol
compound
formula
triglyceride
glucose levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097010871A
Other languages
English (en)
Korean (ko)
Other versions
KR20090081410A (ko
Inventor
안젤로 구글리엘모티
쥬세페 비온디
Original Assignee
아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 filed Critical 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Publication of KR20090081410A publication Critical patent/KR20090081410A/ko
Application granted granted Critical
Publication of KR101413616B1 publication Critical patent/KR101413616B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)
KR1020097010871A 2006-11-24 2007-11-13 트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도 Expired - Fee Related KR101413616B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
ITMI2006A002254 2006-11-24
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (2)

Publication Number Publication Date
KR20090081410A KR20090081410A (ko) 2009-07-28
KR101413616B1 true KR101413616B1 (ko) 2014-07-01

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097010871A Expired - Fee Related KR101413616B1 (ko) 2006-11-24 2007-11-13 트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도

Country Status (23)

Country Link
US (2) US8198310B2 (cg-RX-API-DMAC10.html)
EP (2) EP2409698B1 (cg-RX-API-DMAC10.html)
JP (1) JP5192490B2 (cg-RX-API-DMAC10.html)
KR (1) KR101413616B1 (cg-RX-API-DMAC10.html)
CN (1) CN101541323B (cg-RX-API-DMAC10.html)
AR (1) AR063894A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007323351B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718522A2 (cg-RX-API-DMAC10.html)
CA (1) CA2666371C (cg-RX-API-DMAC10.html)
CY (1) CY1116664T1 (cg-RX-API-DMAC10.html)
DK (2) DK2097080T3 (cg-RX-API-DMAC10.html)
EA (1) EA016885B1 (cg-RX-API-DMAC10.html)
ES (2) ES2403584T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20125570B (cg-RX-API-DMAC10.html)
IL (1) IL198286A (cg-RX-API-DMAC10.html)
IT (1) ITMI20062254A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009004295A (cg-RX-API-DMAC10.html)
PL (2) PL2097080T3 (cg-RX-API-DMAC10.html)
PT (2) PT2097080E (cg-RX-API-DMAC10.html)
SG (1) SG176508A1 (cg-RX-API-DMAC10.html)
SI (2) SI2097080T1 (cg-RX-API-DMAC10.html)
UA (1) UA97123C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008061671A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
BR112012002130A2 (pt) 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
EP3142664B1 (en) * 2014-05-15 2019-12-04 Translatum Medicus Inc. Compositions and methods for treating and diagnosing ocular disorders
AU2019441740B2 (en) 2019-04-18 2025-12-18 Tracery Ophthalmics Inc. Detection, prediction, and classification for ocular disease
EP3990433B1 (en) 2019-06-25 2026-05-20 Translatum Medicus Inc. PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
AU2021297465A1 (en) 2020-06-27 2023-03-02 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534534B1 (en) * 1997-07-28 2003-03-18 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition active in reducing production of MCP-1 protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2605900A1 (en) * 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
EP1959982B1 (en) * 2005-12-01 2012-08-08 Flinders Technologies PTY. Ltd. Methods and compositions for preventing and/or treating pancreatitis
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534534B1 (en) * 1997-07-28 2003-03-18 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition active in reducing production of MCP-1 protein

Also Published As

Publication number Publication date
MX2009004295A (es) 2009-05-05
HK1129071A1 (en) 2009-11-20
WO2008061671A2 (en) 2008-05-29
KR20090081410A (ko) 2009-07-28
PL2097080T3 (pl) 2013-07-31
CY1116664T1 (el) 2017-03-15
EA016885B1 (ru) 2012-08-30
US20100069456A1 (en) 2010-03-18
IL198286A0 (en) 2010-02-17
US8198310B2 (en) 2012-06-12
EP2097080B1 (en) 2013-02-20
HK1165275A1 (en) 2012-10-05
JP2010510263A (ja) 2010-04-02
JP5192490B2 (ja) 2013-05-08
SI2409698T1 (sl) 2015-04-30
EP2097080A2 (en) 2009-09-09
CA2666371A1 (en) 2008-05-29
PT2097080E (pt) 2013-04-01
US20120283307A1 (en) 2012-11-08
AU2007323351B2 (en) 2013-05-02
EP2409698A1 (en) 2012-01-25
ES2403584T3 (es) 2013-05-20
DK2409698T3 (en) 2015-04-27
IL198286A (en) 2016-03-31
SI2097080T1 (sl) 2013-05-31
AU2007323351A1 (en) 2008-05-29
PT2409698E (pt) 2015-02-10
WO2008061671A3 (en) 2008-11-27
CN101541323B (zh) 2012-01-04
SG176508A1 (en) 2011-12-29
GEP20125570B (en) 2012-07-10
DK2097080T3 (da) 2013-05-21
US8846745B2 (en) 2014-09-30
EP2409698B1 (en) 2015-01-21
PL2409698T3 (pl) 2015-06-30
CA2666371C (en) 2014-05-06
ITMI20062254A1 (it) 2008-05-25
ES2530623T3 (es) 2015-03-04
EA200970506A1 (ru) 2009-10-30
CN101541323A (zh) 2009-09-23
BRPI0718522A2 (pt) 2013-11-12
UA97123C2 (uk) 2012-01-10
AR063894A1 (es) 2009-02-25

Similar Documents

Publication Publication Date Title
US8846745B2 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
US20110015206A1 (en) Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
JP2003535888A (ja) 食後のトリグリセリドに富んだリポタンパク質粒子（ｐｐｔｒｌ）の数を低下させるための、ミクロソームのトリグリセリド輸送タンパク質（ｍｔｐ）インヒビターの使用
JP2013173719A (ja) スダチチンを有効成分とする、メタボリックシンドロームの予防及び／又は治療剤
TWI531366B (zh) 牛樟芝在關節炎、軟骨破壞或軟骨細胞死亡的改善或預防的功效
EP4640224A1 (en) Pharmaceutical composition containing sodium-glucose transporter-2 inhibitor and angiotensin ii receptor blocker for prevention or treatment of non-alcoholic fatty liver disease
US9283243B2 (en) CD36 inhibition to control obesity and insulin sensitivity
KR100879253B1 (ko) 에이디피-라이보실 사이클레이즈 억제제를 이용한 고혈압 및 당뇨병성 신증의 치료제
TWI344366B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
EP4640223A1 (en) Pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker
WO1994023721A1 (fr) Nouvelle utilisation medicale d'un derive de dihydropyridine
HK1165275B (en) Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
JP2022506548A (ja) 化合物の抗ｐｃｓｋ９（抗プロタンパク質変換酵素スブチリシン ケキシン９型）ナノ製剤および心血管疾患の治療および／または予防におけるその使用方法
EP1374899B1 (en) Remedies for post-traumatic stress disorder
HK1129071B (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
TW202521110A (zh) 用於肝病之ｆａｓｎ抑制劑及ｇｌｐ－１促效劑之組合
TW202539666A (zh) Gm1神經節苷脂儲積症之治療
TWI671070B (zh) 用於製造與人類凝乳酶的活性相關疾病之預防治療用藥劑之具有黃酮醇骨架之化合物或其藥學上容許之鹽的用途
KR101255939B1 (ko) 4-(1ｈ-인다졸-6-일아미노)-ｎ-아이소프로필-2-(메틸티오)피리미딘-5-카르복스아미드 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는 당뇨병 예방 또는 치료용 조성물
WO2006132245A1 (ja) 腫瘍増殖抑制剤
WO2010148179A1 (en) Method of treating a disorder associated with mtp
MX2007014396A (es) Composicion farmaceutica que comprende 1-(3-clorofenil)-3- alquilpiperazina para el tratamiento de trastorno alimenticio.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170510

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180625

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180625

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301